Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Currency exchange hits Abbott nutritionals: Negative effects from currency exchange help drive down Abbott Nutrition's international revenues from nutritional products by 1.9 percent to $615 million in the firm's fiscal 2009 second quarter, even as U.S. sales grow 10 percent to $668 million. The Abbott Park, Ill.-based company July 15 said a 10.3 percentage point loss from currency exchange slowed nutritional revenues. Its worldwide nutritional sales increased 4 percent despite an unfavorable 5.2 percent effect of exchange rates to $1.28 billion for the April-June period. A 12 percent surge in adult products drove U.S. nutritionals growth to $326 million. Internationally, pediatric formulas continued expanding, growing 3.6 percent, including exchange rate effects, to $354 million. John Thomas, VP of investor relations, said during a same-day earnings call that Abbott expects to launch next-generation Similac and Gain infant formulas in eight more countries this year. He said the reformulated Similac formula and its user-friendly packaging "have been very well received" by customers (1"The Tan Sheet" March 23, 2009)
You may also be interested in...
Abbott, Wockhardt Terminate Nutritional Business Deal
Pharmaceuticals and diagnostics giant Abbott and debt-ridden Indian drug maker Wockhardt call off their $130 million deal for a nutritional business announced less than a year ago
Abbott, Wockhardt Terminate Nutritional Business Deal
Pharmaceuticals and diagnostics giant Abbott and debt-ridden Indian drug maker Wockhardt call off their $130 million deal for a nutritional business announced less than a year ago
Abbott, Wockhardt Terminate Nutritional Business Deal
Pharmaceuticals and diagnostics giant Abbott and debt-ridden Indian drug maker Wockhardt call off their $130 million deal for a nutritional business announced less than a year ago